Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-

[News]

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

More... (https://www.news-medical.net/news/20260730/Dual-immunotherapy-with-neoadjuvant-chemotherapy-shows-encouraging-activity-in-ERBB2-negative-breast-cancer.aspx)